title: Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial.
abstract: Metformin has therapeutic potential against breast cancer, but the mechanisms of action in vivo remain uncertain. This study examined biomarker effects of metformin in primary breast cancer in a preoperative window of opportunity trial. Non-diabetic women with operable invasive breast cancer were randomized to receive open label pre-operative metformin (500 mg daily for 1 week then 1 g twice daily for a further week) or as controls, not receiving metformin. Patients in both arms had a core biopsy pre-randomisation and again at the time of surgery. Immunohistochemistry for phospho-AMPK (pAMPK), phospho-Akt (pAkt), insulin receptor, cleaved caspase-3, and Ki67 was performed on formalin-fixed paraffin-embedded cores, scored blinded to treatment and analysed by paired t test. In metformin-treated patients, significant up-regulation of pAMPK (paired t test, p = 0.04) and down-regulation of pAkt (paired t test, p = 0.043) were demonstrated compared to the control group. Insulin receptor and serum insulin remained similar following metformin treatment compared with a rise in insulin receptor and insulin in controls. Significant falls in Ki67 and cleaved caspase-3 (paired t test, p = 0.044) were seen in the metformin-treated patients but not in the control group. Changes were independent of body mass index. These biomarker data suggest mechanisms for metformin action in vivo in breast cancer patients via up-regulation of tumor pAMPK, down-regulation of pAkt, and suppression of insulin responses reflecting cytostatic rather than cytotoxic mechanisms.
authors: Academic Department of Surgical Oncology, University of Sheffield, Sheffield, UK, s.hadad@sheffield.ac.uk.
authors: Sirwan M
authors: SM
authors: Hadad
authors: Philip
authors: P
authors: Coates
authors: Lee B
authors: LB
authors: Jordan
authors: Ryan J O
authors: RJ
authors: Dowling
authors: Martin C
authors: MC
authors: Chang
authors: Susan J
authors: SJ
authors: Done
authors: Colin A
authors: CA
authors: Purdie
authors: Pamela J
authors: PJ
authors: Goodwin
authors: Vuk
authors: V
authors: Stambolic
authors: Stacy
authors: S
authors: Moulder-Thompson
authors: Alastair M
authors: AM
authors: Thompson
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D053148:Caspase 3 / Q000378:metabolism; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism; D008687:Metformin / Q000008:administration & dosage / Q000627:therapeutic use*; D020360:Neoadjuvant Therapy; D010766:Phosphorylation; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D011972:Receptor, Insulin / Q000378:metabolism; D015398:Signal Transduction; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D019394:Ki-67 Antigen; D008687:Metformin; D011972:Receptor, Insulin; D051057:Proto-Oncogene Proteins c-akt; D053148:Caspase 3